Review Micro/nanorobotics for sepsis diagnosis and therapy: a frontier in precision medicine Full text PDF
Research Paper PEGylated IL2 and tumor-targeted radiotherapy augment CD8+ T cell-mediated anti-tumor response to anti-PD-1 in head and neck squamous cell carcinoma Full text PDF
Research Paper Targeting USP22 reprograms the tumor microenvironment and sensitizes KRAS/p53-driven lung cancer to anti-PD-1 immunotherapy Full text PDF
Research Paper Cardiomyocyte-Specific RNF128 Attenuates Pathological Cardiac Hypertrophy Progression by Stabilizing SERCA2a through Lys63-Linked Polyubiquitination Full text PDF
Research Paper Mapping endometrial vascular functional gradients using depth-derived ultrasound localization microscopy (D-ULM) for early stratification of postinjury fibrotic remodeling and therapeutic guidance Full text PDF
Research Paper Lactylation at H3K18 drives pathological angiogenesis via metabolic-epigenetic crosstalk in ischemic retinopathy Full text PDF
Issue 13; 2026
Founding Editor-in-Chief:
Prof. Xiaoyuan (Shawn) Chen, PhD
Profile
Theranostics publishes innovative research articles reflecting the fields of in vitro diagnostics and prognostics, in vivo molecular imaging, molecular therapeutics, image-guided therapy, biosensors, system biology and translational medicine, personalized medicine and a broad spectrum of biomedical research that can be applied to future theranostic applications.
Pathological cardiac hypertrophy is maladaptive cardiac remodeling induced by chronic adverse stimuli. In this study, the E3 ubiquitin ligase RNF128 was identified as a suppressor of pathological cardiac dysfunction with therapeutic value. Methods: The expression of Ring Finger protein 128 (RNF128) in pathological cardiac hypertrophy was characterized via public database analysis, scRNA-seq (single-cell RNA sequencing), and further validated in clinical ...